# Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

> **NCT00738673** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** degarelix

## Key facts

- **NCT ID:** NCT00738673
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738673, "Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00738673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*